James Cates
Family Medicine · Cookeville, TNNPI 1073517892
Payments from drug & device makers
Across 124 payments — averaging $15.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$754
- AstraZeneca$330
- AbbVie$161
- Johnson & Johnson$123
- Lilly USA, LLC$119
- GSK$81
- plus $403 from 15 others
What the payments were for
- Food & beverage$1,966100%
- Education$60%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 54 | $754 |
| AstraZeneca | 13 | $330 |
| AbbVie | 10 | $161 |
| Johnson & Johnson(2 entities) | 8 | $123 |
| Lilly USA, LLC | 8 | $119 |
| GSK | 5 | $81 |
| Philips North America LLC | 4 | $55 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $52 |
| Abbott | 3 | $50 |
| Azurity Pharmaceuticals, Inc. | 3 | $50 |
| Genentech USA, Inc. | 3 | $38 |
| Lundbeck LLC | 1 | $22 |
| Corcept Therapeutics | 1 | $22 |
| Amgen | 1 | $21 |
| Bayer | 1 | $15 |
| Pfizer | 1 | $15 |
| Astellas Pharma US Inc | 1 | $14 |
| Dexcom, Inc. | 1 | $13 |
| Arbor Pharmaceuticals, Inc. | 1 | $13 |
| Boehringer Ingelheim | 1 | $12 |
| Sanofi Pasteur Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$123
How this compares
$1,972 in reported general payments places this provider in the 65th percentile of 2,087 family medicine providers in Tennessee.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 24 | $27,480 |
| FarxigaDapagliflozin Propanediol | 23 | $22,846 |
| OzempicSemaglutide | 11 | $20,212 |
| LinzessLinaclotide | 11 | $5,988 |
| Dexlansoprazole DrDexlansoprazole | 13 | $3,259 |
| Gabapentin | 113 | $1,410 |
| Rosuvastatin Calcium | 95 | $1,301 |
| Valsartan | 25 | $1,253 |
| Levothyroxine Sodium | 120 | $1,247 |
| Clonazepam | 97 | $846 |
| Celecoxib | 20 | $771 |
| Pregabalin | 43 | $738 |
| Metoprolol Succinate | 24 | $723 |
| Testosterone Cypionate | 14 | $634 |
| Zolpidem Tartrate | 48 | $614 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $15 | $27,48024 claims |
| AstraZenecaFarxiga | $330 | $22,84623 claims |
| Novo NordiskOzempic | $754 | $20,21211 claims |
| AbbVieLinzess | $161 | $5,98811 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 2,087 family medicine providers in Tennessee.
Other family medicine in Cookeville
- Rickey ManningKnoxville$8.1M
- Kymberly MoyerGallatin$5.9M
- Natasha BallardChattanooga$5.7M
- Hina BudhwaniNashville$4.7M
- Paul WakefieldKnoxville$4.3M
- Emily HubbsKingsport$2.8M
- Jerry PunchKnoxville$2.1M
- Bridgette FraneyNashville$2M
- Andrew BrockmyreBristol$1.8M
- Marcus LeeTullahoma$1.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.